Descartes Study Finds 67% of Freight Forwarders and Customs Brokers View Technology as Fundamental to Growth
Automation and AI emerge as critical differentiators for logistics services providers facing…
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing…
Study Finds ELISAs in Milk Samples Less Reliable for Johne’s Disease Detection — $198M in Dairy Losses Underscore Need for More Accurate Milk Testing
Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling…
BML Munjal University to host Leadership Summit on Youth Entrepreneurship and Start-up Governance
NEW DELHI, Oct. 29, 2025 /PRNewswire/ -- BML Munjal University (BMU), a…
Two-thirds of surveyed enterprises in EMEA report significant productivity gains from AI, finds new IBM study
66% of responding senior leaders say AI has already driven significant productivity…
Updated IOC report shows 86 per cent of all permanent Olympic venues still in use
23 October 2025 - An updated analysis of venues shows that 86 per…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…